Evenity (Romosozumab) Medicare Part D Coverage: What You Actually Pay in 2026

How Medicare Part D Classifies Evenity

Most Part D plans place romosozumab on specialty Tier 5, which carries the highest cost-sharing bracket. Before the Inflation Reduction Act (IRA) provisions took effect in 2025, a Medicare beneficiary filling a specialty drug could face 25% coinsurance in the coverage gap and 5% in catastrophic coverage, producing annual out-of-pocket bills exceeding $5,000 for Evenity alone.

The IRA changed the math. Starting January 1, 2025, all Part D enrollees have a hard $2,000 annual out-of-pocket maximum across every covered drug (CMS IRA fact sheet). Once you hit that threshold, you pay nothing more for the rest of the calendar year. For a 12-month Evenity course at roughly $1,825 per injection, most patients will reach the $2,000 cap within the first one to two fills, making the remaining 10 to 11 doses effectively free from the patient's perspective.

Plans also offer the Medicare Prescription Payment Plan, which lets you spread the $2,000 maximum into predictable monthly installments rather than paying it all at the pharmacy counter during your first fill. You can enroll by calling your Part D plan or through Medicare.gov.

Prior Authorization and Step Therapy Requirements

Expect paperwork. Almost every Part D plan requires prior authorization before approving romosozumab. Your prescribing physician will need to document a confirmed diagnosis of osteoporosis (typically a DXA T-score of −2.5 or below at the lumbar spine, femoral neck, or total hip), high fracture risk, and in many cases a history of fragility fracture (AACE 2020 osteoporosis guidelines).

Some plans impose step therapy, meaning you must have tried and failed (or be documented as intolerant to) a bisphosphonate such as alendronate or zoledronic acid before the plan will approve Evenity. The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months, and the ARCH trial (N=4,093) showed a 48% lower risk of new vertebral fracture compared to alendronate at 24 months (Cosman F et al., NEJM 2016, Saag KG et al., NEJM 2017). Your physician can cite these data in the prior authorization letter to argue that first-line romosozumab is medically necessary, particularly if you have very high fracture risk or a recent fracture.

Denials happen. If your plan denies coverage, you have the right to file a formal appeal and, if needed, request an Independent Review Entity decision. The whole appeals process is outlined in your plan's Evidence of Coverage document.

Part B vs. Part D: Two Paths to Coverage

Romosozumab is a subcutaneous injection, and where it is administered determines which part of Medicare pays for it. This distinction matters.

If your physician administers Evenity in the office, the drug may be billed under Medicare Part B as a physician-administered injectable. Under Part B, you typically owe 20% coinsurance after meeting the annual Part B deductible ($257 in 2025). For a single $1,825 dose, that works out to approximately $365 per injection, or about $4,380 over 12 months, assuming no supplemental coverage.

A Medigap plan (Medicare Supplement) can erase most or all of that Part B coinsurance. Plan F, Plan G, and several other letter plans cover the 20% coinsurance, which would bring your out-of-pocket cost close to zero for in-office Evenity.

If you fill Evenity at a specialty pharmacy and self-inject (or have a caregiver inject), the claim runs through Part D instead, and the $2,000 IRA cap applies. Which route costs less depends entirely on whether you carry a Medigap policy or a Part D plan with favorable specialty-tier terms. Ask your plan and your Medigap insurer to run the numbers both ways before your first fill.

What the $2,000 Cap Actually Looks Like Month by Month

Here is a realistic cost timeline for a Medicare Part D enrollee starting Evenity in January 2026 without any supplemental assistance program.

The Part D deductible for 2026 has not been finalized at time of writing, but the 2025 deductible was $590. Assume a similar figure. Your first fill in January triggers the full deductible plus Tier 5 coinsurance (commonly 25% to 33%). That single fill will likely push you to or very near the $2,000 annual cap. February's fill may carry a small residual balance. Fills three through twelve cost you zero dollars.

If you enroll in the Medicare Prescription Payment Plan, the $2,000 is divided into equal monthly installments across the remaining months in the calendar year. Starting in January means roughly $167 per month. Starting mid-year means higher monthly installments over fewer months, so beginning treatment in January is financially optimal when possible.

The IRA cap applies to all Part D drug spending combined. If you take other expensive medications, the $2,000 ceiling is shared across them. You will not pay $2,000 for Evenity plus $2,000 for another drug. The total across all Part D drugs is $2,000. Period.

Amgen Patient Assistance and Copay Programs

Amgen runs two primary support programs for Evenity. Know which one applies to you.

Amgen FIRST STEP Program. This is a copay assistance card for commercially insured patients. It can reduce out-of-pocket costs to as low as $5 per month. The catch: it is not valid for anyone enrolled in a federal healthcare program, including Medicare, Medicaid, Tricare, or VA benefits. If you are on Medicare, you cannot use this card. Full stop.

Amgen Safety Net Foundation. This is a separate, independent charitable foundation that provides Evenity at no cost to patients who meet income and insurance criteria. Medicare patients are eligible to apply. The foundation evaluates household income (generally at or below 400% of the Federal Poverty Level, though thresholds can shift). Applications require income documentation and a prescription from your physician. Processing takes approximately two to four weeks (Amgen Safety Net Foundation).

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "The single biggest barrier to romosozumab use is not clinical evidence. It is the administrative burden of getting the drug approved and paid for." That observation tracks with data from the National Osteoporosis Foundation showing that fewer than 25% of high-risk fracture patients receive any osteoporosis pharmacotherapy within 12 months of a fragility fracture (Solomon DH et al., J Bone Miner Res 2014).

Other Ways to Lower Your Evenity Cost

Beyond the two Amgen programs, several additional strategies can reduce what you pay.

State Pharmaceutical Assistance Programs (SPAPs). More than 20 states operate SPAPs that supplement Medicare Part D by covering premiums, deductibles, or copays. Eligibility and benefit levels vary by state. The Medicare.gov Plan Finder tool lists available SPAPs for your ZIP code.

Extra Help (Low-Income Subsidy). If your annual income is below $22,590 (individual) or $30,660 (couple) and your countable resources fall below set thresholds, you may qualify for Medicare Extra Help, which can reduce Part D premiums, deductibles, and copays to near zero. The Social Security Administration processes Extra Help applications (SSA Extra Help page).

Charitable copay foundations. Organizations such as the HealthWell Foundation and the Patient Access Network (PAN) Foundation periodically open funds for osteoporosis medications. Fund availability fluctuates. Check their websites early in the calendar year, as many funds open in January and close quickly.

Specialty pharmacy negotiation. Some specialty pharmacies offer cash-pay discounts or will match competitor pricing. If you are in the Part D donut hole or have not yet hit your deductible, asking the pharmacy about their cash price compared to your insurance cost-share is worth the phone call.

The Cardiovascular Black-Box Warning and Its Effect on Coverage

Romosozumab carries an FDA black-box warning for potential increased risk of myocardial infarction, stroke, and cardiovascular death. The warning is based on findings from the ARCH trial, where 2.5% of romosozumab-treated patients experienced a major adverse cardiovascular event (MACE) over 12 months versus 1.9% in the alendronate arm (FDA Evenity prescribing information). The difference was not statistically significant after adjustment, but the FDA applied the warning based on a numerical imbalance.

This warning has practical consequences for coverage. Some Part D plans use the cardiovascular risk profile as grounds for stricter prior authorization criteria. Your prescriber may need to document a cardiovascular risk assessment and confirm that you have no history of MI or stroke within the past year. The Endocrine Society's 2020 guidelines recommend avoiding romosozumab in patients with recent cardiovascular events (Shoback D et al., JCEM 2020).

The label does not contraindicate romosozumab in all patients with cardiovascular risk factors. It contraindicates use in patients who have had an MI or stroke within the preceding year. For patients without recent events, the prescriber's clinical judgment and documentation of risk-benefit assessment is typically sufficient to secure approval.

Timing Your Treatment for Maximum Coverage Benefit

Romosozumab is dosed once monthly for 12 consecutive months. You cannot pause and restart. Once you begin, the clinical protocol calls for completing all 12 doses, then transitioning to an anti-resorptive agent (usually denosumab or a bisphosphonate) to maintain the bone density gains.

Calendar-year timing matters under Part D because the $2,000 cap resets every January 1. If you start Evenity in January, you hit the cap early and ride $0 copays for the remaining 10 to 11 months of treatment, all within one calendar year. Start in July, and your 12-month course spans two calendar years, potentially requiring you to hit the $2,000 cap twice, once in each year. That is $4,000 versus $2 to 000 in total out-of-pocket cost, purely based on start date.

Coordinate with your physician to begin treatment in January or February whenever clinically appropriate. If an acute fracture or very high imminent fracture risk demands starting mid-year, the math still favors Evenity over untreated osteoporosis. A single hip fracture costs the healthcare system approximately $40,000 to $50 to 000 in the first year and carries a 20% to 24% one-year mortality rate in adults over 65 (Haentjens P et al., Ann Intern Med 2010).

What Happens After the 12-Month Evenity Course

Romosozumab's bone-forming effect reverses rapidly if not followed by anti-resorptive therapy. In the FRAME trial extension, patients who received romosozumab for 12 months followed by denosumab for 12 months maintained a total hip BMD gain of 6.9% at month 24, while those who received placebo then denosumab gained only 3.2% (Cosman F et al., JCEM 2018).

The transition drug matters for cost planning. Denosumab (Prolia) is administered by subcutaneous injection every six months and is typically billed under Medicare Part B. Zoledronic acid (Reclast) is an annual IV infusion, also billed under Part B. Generic alendronate is a daily or weekly oral tablet costing under $15 per month at most pharmacies.

Plan your post-Evenity therapy before your first Evenity dose so you can budget the full treatment sequence, not just the first 12 months.

Real-World Coverage Approval Rates

No publicly available dataset breaks down Part D prior authorization approval rates for romosozumab specifically. Anecdotal data from large osteoporosis practices suggest first-pass approval rates of roughly 60% to 70% when documentation is complete, with appeal success rates of about 50% for initial denials.

The American Association of Clinical Endocrinology (AACE) recommends that clinicians submit prior authorization requests that include: DXA T-score results, FRAX score (if applicable), fracture history, documentation of bisphosphonate trial or contraindication, cardiovascular risk statement, and a letter of medical necessity citing the ARCH or FRAME trials (AACE 2020 guidelines).

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research & Osteoporosis Center, has noted: "Physicians who provide detailed fracture-risk documentation at the first submission see significantly fewer denials than those who submit minimal clinical notes."

Step-by-Step Checklist to Get Evenity Covered Under Part D

Follow this sequence to minimize delays and out-of-pocket cost.

1. Confirm your Part D plan's formulary includes romosozumab. Use Medicare.gov Plan Finder or call your plan directly.
2. Ask your plan whether Evenity is Tier 4 or Tier 5, and whether step therapy applies.
3. Have your physician prepare a prior authorization submission with DXA scores, FRAX score, fracture history, cardiovascular clearance, and trial citations.
4. If denied, file a formal appeal within 60 days. Include updated clinical documentation.
5. Apply for Amgen Safety Net Foundation assistance if your household income is at or below 400% FPL.
6. Check HealthWell Foundation and PAN Foundation osteoporosis funds for copay support.
7. Enroll in the Medicare Prescription Payment Plan to spread the $2,000 cap across monthly installments.
8. Schedule your first injection in January to keep the entire 12-month course within one calendar year.
9. Confirm your post-Evenity anti-resorptive plan and its coverage pathway (Part B vs. Part D) before starting treatment.